Algeta's lead product candidate, Alpharadin, has commenced phase III clinical trials in hormone-refractory prostate cancer based on positive phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.
Algeta is also developing other technologies for delivering alpha emitters. The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Alpharadin is a unique targeted treatment for skeletal metastases in cancer patients and is based on radium-223. The clinical development of Alpharadin is most advanced in hormone refractory prostate cancer (HRPC) that has spread to bone, where it is now in an international phase III trial. In a phase II trial completed in 2007 involving 64 men with metastatic HRPC, Alpharadin was shown to increase life expectancy by over 40%, and was found to be exceptionally well tolerated.
Clinical data from this and other trials suggest Alpharadin may also have a role in the treatment of other high-incidence metastatic cancers.
Algeta began its pivotal phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study in mid-2008 and it is now ongoing in several countries in Europe. Approximately 750 patients are expected to be enrolled at more than 125 medical centers in Europe, Asia, South America and Canada. The international trial is evaluating Alpharadin in metastatic HRPC with overall survival as the primary endpoint.
Alpharadin in also in a phase I trial in the USA under Investigational
|SOURCE Algeta ASA|
Copyright©2008 PR Newswire.
All rights reserved